Company

Vericel Corporation

Headquarters: Cambridge, MA, United States

Founded: 1989 

Employees: 281

CEO: Mr. Dominick C. Colangelo Esq.

NASDAQ: VCEL +4.23%

Market Cap

$2.27 Billion

USD as of July 1, 2024

Market Cap History

Vericel Corporation market capitalization over time

Evolution of Vericel Corporation market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Vericel Corporation

Detailed Description

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Vericel Corporation has the following listings and related stock indices.


Stock: NASDAQ: VCEL wb_incandescent

Stock: FSX: ATQP wb_incandescent

Product & Services

MACIEpicelCarticel

Key People

Nick Colangelo (CEO) Daniel Orlando (COO) Gerard Michel (CFO)

Details

Headquarters:

64 Sidney Street

Cambridge, MA 02139

United States

Phone: 617 588 5555

Fax: 617 588 5554